ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.493
-0.037 (-7.00%)
At close: Jan 21, 2025, 4:00 PM
0.630
+0.137 (27.79%)
After-hours: Jan 21, 2025, 7:59 PM EST
ImmunoPrecise Antibodies Revenue
ImmunoPrecise Antibodies had revenue of 6.13M CAD in the quarter ending October 31, 2024, a decrease of -0.41%. This brings the company's revenue in the last twelve months to 24.07M, up 6.36% year-over-year. In the fiscal year ending April 30, 2024, ImmunoPrecise Antibodies had annual revenue of 24.52M with 18.65% growth.
Revenue (ttm)
24.07M CAD
Revenue Growth
+6.36%
P/S Ratio
0.83
Revenue / Employee
238,307 CAD
Employees
101
Market Cap
16.53M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2024 | 24.52M | 3.85M | 18.65% |
Apr 30, 2023 | 20.67M | 1.30M | 6.72% |
Apr 30, 2022 | 19.36M | 1.45M | 8.11% |
Apr 30, 2021 | 17.91M | 3.85M | 27.42% |
Apr 30, 2020 | 14.06M | 3.13M | 28.66% |
Apr 30, 2019 | Pro | Pro | Pro |
Apr 30, 2018 | Pro | Pro | Pro |
Apr 30, 2017 | Pro | Pro | Pro |
Apr 30, 2016 | Pro | Pro | Pro |
Apr 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
IPA News
- 4 days ago - ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Business Wire
- 21 days ago - IPA Announces Resignation of Chief Financial Officer - Business Wire
- 22 days ago - $116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors - Business Wire
- 4 weeks ago - ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases - Business Wire
- 4 weeks ago - IPA to Present at The Microcap Conference 2025 - Accesswire
- 6 weeks ago - ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 - Business Wire
- 6 weeks ago - IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Business Wire